Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine

Elisabetta Ferraro, Fabrizio Pin, Stefania Gorini, Laura Pontecorvo, Alberto Ferri, Vincenzo Mollace, Paola Costelli, Giuseppe Rosano

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: The loss of muscle mass (sarcopenia) and the associated reduced muscle strength are key limiting factors for elderly people's quality of life. Improving muscle performance does not necessarily correlate with increasing muscle mass. In fact, particularly in the elderly, the main explanation for muscle weakness is a reduction of muscle quality rather than a loss of muscle mass, and the main goal to be achieved is to increase muscle strength. The effectiveness of Trimetazidine (TMZ) in preventing muscle functional impairment during ageing was assessed in our laboratory. Methods: Aged mice received TMZ or vehicle for 12 consecutive days. Muscle function was evaluated at the end of the treatment by a grip test as well as by an inverted screen test at 0, 5, 7 and 12 days of TMZ treatment. After sacrifice, muscles were stored for myofiber cross-sectional area assessment and myosin heavy chain expression evaluation by western blotting. Results: Chronic TMZ treatment does not affect the mass of both gastrocnemius and tibialis anterior muscles, while it significantly increases muscle strength. Indeed, both latency to fall and grip force are markedly enhanced in TMZ-treated versus untreated mice. In addition, TMZ administration results in higher expression of slow myosin heavy chain isoform and increased number of small-sized myofibers. Conclusions: We report here some data showing that the modulation of skeletal muscle metabolism by TMZ increases muscle strength in aged mice. Reprogramming metabolism might therefore be a strategy worth to be further investigated in view of improving muscle performance in the elderly.

Original languageEnglish
JournalJournal of Cachexia, Sarcopenia and Muscle
DOIs
Publication statusAccepted/In press - 2015

Fingerprint

Trimetazidine
Skeletal Muscle
Muscles
Muscle Strength
Myosin Heavy Chains
Hand Strength
Sarcopenia
Muscle Weakness
Protein Isoforms
Therapeutics
Western Blotting

Keywords

  • Aging, Exercise pill
  • Metabolic reprogramming
  • Neuro-rehabilitation
  • Sarcopenia

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physiology (medical)

Cite this

Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. / Ferraro, Elisabetta; Pin, Fabrizio; Gorini, Stefania; Pontecorvo, Laura; Ferri, Alberto; Mollace, Vincenzo; Costelli, Paola; Rosano, Giuseppe.

In: Journal of Cachexia, Sarcopenia and Muscle, 2015.

Research output: Contribution to journalArticle

Ferraro, Elisabetta ; Pin, Fabrizio ; Gorini, Stefania ; Pontecorvo, Laura ; Ferri, Alberto ; Mollace, Vincenzo ; Costelli, Paola ; Rosano, Giuseppe. / Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. In: Journal of Cachexia, Sarcopenia and Muscle. 2015.
@article{fa33a119547f46499674f3533838aa39,
title = "Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine",
abstract = "Background: The loss of muscle mass (sarcopenia) and the associated reduced muscle strength are key limiting factors for elderly people's quality of life. Improving muscle performance does not necessarily correlate with increasing muscle mass. In fact, particularly in the elderly, the main explanation for muscle weakness is a reduction of muscle quality rather than a loss of muscle mass, and the main goal to be achieved is to increase muscle strength. The effectiveness of Trimetazidine (TMZ) in preventing muscle functional impairment during ageing was assessed in our laboratory. Methods: Aged mice received TMZ or vehicle for 12 consecutive days. Muscle function was evaluated at the end of the treatment by a grip test as well as by an inverted screen test at 0, 5, 7 and 12 days of TMZ treatment. After sacrifice, muscles were stored for myofiber cross-sectional area assessment and myosin heavy chain expression evaluation by western blotting. Results: Chronic TMZ treatment does not affect the mass of both gastrocnemius and tibialis anterior muscles, while it significantly increases muscle strength. Indeed, both latency to fall and grip force are markedly enhanced in TMZ-treated versus untreated mice. In addition, TMZ administration results in higher expression of slow myosin heavy chain isoform and increased number of small-sized myofibers. Conclusions: We report here some data showing that the modulation of skeletal muscle metabolism by TMZ increases muscle strength in aged mice. Reprogramming metabolism might therefore be a strategy worth to be further investigated in view of improving muscle performance in the elderly.",
keywords = "Aging, Exercise pill, Metabolic reprogramming, Neuro-rehabilitation, Sarcopenia",
author = "Elisabetta Ferraro and Fabrizio Pin and Stefania Gorini and Laura Pontecorvo and Alberto Ferri and Vincenzo Mollace and Paola Costelli and Giuseppe Rosano",
year = "2015",
doi = "10.1002/jcsm.12097",
language = "English",
journal = "Journal of Cachexia, Sarcopenia and Muscle",
issn = "2190-5991",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine

AU - Ferraro, Elisabetta

AU - Pin, Fabrizio

AU - Gorini, Stefania

AU - Pontecorvo, Laura

AU - Ferri, Alberto

AU - Mollace, Vincenzo

AU - Costelli, Paola

AU - Rosano, Giuseppe

PY - 2015

Y1 - 2015

N2 - Background: The loss of muscle mass (sarcopenia) and the associated reduced muscle strength are key limiting factors for elderly people's quality of life. Improving muscle performance does not necessarily correlate with increasing muscle mass. In fact, particularly in the elderly, the main explanation for muscle weakness is a reduction of muscle quality rather than a loss of muscle mass, and the main goal to be achieved is to increase muscle strength. The effectiveness of Trimetazidine (TMZ) in preventing muscle functional impairment during ageing was assessed in our laboratory. Methods: Aged mice received TMZ or vehicle for 12 consecutive days. Muscle function was evaluated at the end of the treatment by a grip test as well as by an inverted screen test at 0, 5, 7 and 12 days of TMZ treatment. After sacrifice, muscles were stored for myofiber cross-sectional area assessment and myosin heavy chain expression evaluation by western blotting. Results: Chronic TMZ treatment does not affect the mass of both gastrocnemius and tibialis anterior muscles, while it significantly increases muscle strength. Indeed, both latency to fall and grip force are markedly enhanced in TMZ-treated versus untreated mice. In addition, TMZ administration results in higher expression of slow myosin heavy chain isoform and increased number of small-sized myofibers. Conclusions: We report here some data showing that the modulation of skeletal muscle metabolism by TMZ increases muscle strength in aged mice. Reprogramming metabolism might therefore be a strategy worth to be further investigated in view of improving muscle performance in the elderly.

AB - Background: The loss of muscle mass (sarcopenia) and the associated reduced muscle strength are key limiting factors for elderly people's quality of life. Improving muscle performance does not necessarily correlate with increasing muscle mass. In fact, particularly in the elderly, the main explanation for muscle weakness is a reduction of muscle quality rather than a loss of muscle mass, and the main goal to be achieved is to increase muscle strength. The effectiveness of Trimetazidine (TMZ) in preventing muscle functional impairment during ageing was assessed in our laboratory. Methods: Aged mice received TMZ or vehicle for 12 consecutive days. Muscle function was evaluated at the end of the treatment by a grip test as well as by an inverted screen test at 0, 5, 7 and 12 days of TMZ treatment. After sacrifice, muscles were stored for myofiber cross-sectional area assessment and myosin heavy chain expression evaluation by western blotting. Results: Chronic TMZ treatment does not affect the mass of both gastrocnemius and tibialis anterior muscles, while it significantly increases muscle strength. Indeed, both latency to fall and grip force are markedly enhanced in TMZ-treated versus untreated mice. In addition, TMZ administration results in higher expression of slow myosin heavy chain isoform and increased number of small-sized myofibers. Conclusions: We report here some data showing that the modulation of skeletal muscle metabolism by TMZ increases muscle strength in aged mice. Reprogramming metabolism might therefore be a strategy worth to be further investigated in view of improving muscle performance in the elderly.

KW - Aging, Exercise pill

KW - Metabolic reprogramming

KW - Neuro-rehabilitation

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=84953320859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953320859&partnerID=8YFLogxK

U2 - 10.1002/jcsm.12097

DO - 10.1002/jcsm.12097

M3 - Article

JO - Journal of Cachexia, Sarcopenia and Muscle

JF - Journal of Cachexia, Sarcopenia and Muscle

SN - 2190-5991

ER -